Safety Study of Infusion of SGT-53 to Treat Solid Tumors
NCT00470613
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm
Interventions
GENETIC:
SGT-53
Sponsor
SynerGene Therapeutics, Inc.